NCT00418431

Brief Summary

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment. The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2006

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2006

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2006

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2006

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 3, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 4, 2007

Completed
Last Updated

June 5, 2024

Status Verified

June 1, 2024

Enrollment Period

Same day

First QC Date

January 3, 2007

Last Update Submit

June 3, 2024

Conditions

Central Serous Chorioretinopathy

Interventions

Intravitreal injection of BevacizumabDRUG

Eligibility Criteria

Age20 Years - 50 Years
Sexall
Age GroupsAdult (18-64)

You may qualify if:

  • Any visual acuity.
  • Central serous chorioretinopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, 04030, Mexico

Location

MeSH Terms

Conditions

Central Serous Chorioretinopathy

Condition Hierarchy (Ancestors)

Retinal DiseasesEye Diseases

Study Officials

  • Mitzy E Torres Soriano, MD

    Asociación para Evitar la Ceguera en México

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 3, 2007

First Posted

January 4, 2007

Study Start

April 1, 2006

Primary Completion

April 1, 2006

Study Completion

August 1, 2006

Last Updated

June 5, 2024

Record last verified: 2024-06

Locations

ME(1)